V4Cure
French tech company | Builders Republic
About
Biotech spun out of the CEA that turns animal venom peptides into synthetic drug candidates — its lead compound V4C-232, derived from green mamba venom, targets refractory ascites in liver cirrhosis, a complication with no approved drug treatment, while V4C-233 addresses polycystic kidney disease, both in late preclinical and regulatory development ahead of a clinical trial application.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2023
- City
- SAINT-CLOUD
- Region
- IDF
- Tracked rounds
- 2
- Amount raised
- 2.4 M€ raised since 2020
Funding rounds
- Seed · 2026
- Pre-seed · 2023